Organigram Further Expands Global Portfolio with Launch of Edison and BOXHOT Medical Vapes and Pastilles in Australia

Executive Summary

• Organigram Global Inc. announced the launch of its Edison and BOXHOT medical‑cannabis vape and pastille products in Australia, introducing 10 new SKUs to the market.
• The rollout coincides with Organigram’s proposed acquisition of Germany’s Sanity Group, underscoring a broader international expansion strategy.
• Products will be distributed nationwide through Leafio (Montu Australia), reaching over 4,000 pharmacies and will be showcased at the United in Compassion Medical Cannabis Symposium in Brisbane (Feb 26‑28).

Key Details

• Product Portfolio: 10 SKUs across Edison (vapes with single‑strain live terpenes) and BOXHOT (1.2 g wide‑bodied cartridges) brands; pastille range featuring established formulations for specific patient experiences.
• Distribution Partner: Leafio, the wholesale arm of Montu Australia, providing access to >4,000 Australian pharmacies via a national supply chain.
• Strategic Timing: Launch announced alongside Organigram’s pending acquisition of Sanity Group, a leading German cannabis company, highlighting a coordinated international growth plan.
• Market Context: Australia identified as one of the world’s fastest‑growing medical‑cannabis markets, with increasing approvals and a shift toward non‑flower dosage forms (vapes, pastilles).
• Promotional Activity: Organigram will sponsor the United in Compassion (UIC) Medical Cannabis Symposium (Feb 26‑28, Brisbane); Senior VP Borna Zlamalik to present “From Potency to Predictability: Engineering Confidence in Medical Cannabis.”
• Executive Commentary:
• Megan McCrae (SVP, Corporate Strategy & International Growth) emphasized the launch as a pivotal step aligning with the Sanity Group acquisition and Organigram’s global expansion.
• Borna Zlamalik (SVP, Innovation & International R&D) highlighted the company’s science‑led advantage in delivering reliable, ready‑to‑consume products to the Australian market.

Notable Quotes

• “Australia represents an exciting international opportunity in medical cannabis… The launch of Organigram brands in Australia coincides with our proposed acquisition of Sanity Group… ” – Megan McCrae, Senior Vice President, Corporate Strategy & International Growth.
• “Our industry‑leading focus on science and clinical validation… give us a unique advantage as we introduce our established Canadian brands and product offerings to the Australian market.” – Borna Zlamalik, Senior Vice President, Innovation and International R&D.